<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>KFF Health News</provider_name><provider_url>https://kffhealthnews.org</provider_url><author_name>Lydia Zuraw</author_name><author_url>https://kffhealthnews.org/news/author/khnlydia/</author_url><title>Facebook Live: It&#x2019;s 2018, Can Big Pharma Hold The Line Against Pricing Controls? - KFF Health News</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="BTnOPLgVF7"&gt;&lt;a href="https://kffhealthnews.org/news/facebook-live-its-2018-can-big-pharma-hold-the-line-against-pricing-controls/"&gt;Facebook Live: It&#x2019;s 2018, Can Big Pharma Hold The Line Against Pricing Controls?&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/news/facebook-live-its-2018-can-big-pharma-hold-the-line-against-pricing-controls/embed/#?secret=BTnOPLgVF7" width="600" height="338" title="&#x201C;Facebook Live: It&#x2019;s 2018, Can Big Pharma Hold The Line Against Pricing Controls?&#x201D; &#x2014; KFF Health News" data-secret="BTnOPLgVF7" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://kffhealthnews.org/wp-content/uploads/sites/2/2018/01/fblive-011018.jpg</thumbnail_url><thumbnail_width>770</thumbnail_width><thumbnail_height>513</thumbnail_height><description>In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry&#x2019;s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.</description></oembed>
